Orfiril Long (Sodium Valproate)

Sodium valproate enhances the activity of the inhibitory neurotransmitter GABA by inhibiting its breakdown and increasing its synthesis. It also blocks voltage‑gated sodium channels and modulates calcium currents, which together lower neuronal firing rates and help control seizures, stabilize mood, and prevent migraines.

The appropriate dose of Orfiril Long is individualized by the prescribing clinician based on the patient’s age, weight, indication, and response to therapy. Dosage adjustments are made according to clinical response and laboratory monitoring, and patients should follow the prescriber’s specific instructions.

Sodium valproate is associated with a known risk of birth defects and developmental disorders when used during pregnancy. It is generally avoided unless no suitable alternative exists. Use while breastfeeding is also discouraged because the drug is excreted in breast milk. Consultation with a specialist is essential before use in these situations.

To request Orfiril Long, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with other anticonvulsants such as carbamazepine or phenytoin, sodium valproate offers broader spectrum seizure control and additional mood‑stabilizing properties. However, it carries a higher risk of hepatic toxicity and teratogenicity, requiring more intensive monitoring and caution in women of child‑bearing potential.

Orfiril Long tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Orfiril Long is taken orally, usually once daily due to its extended‑release formulation. The tablet should be swallowed whole with water and not crushed, chewed, or broken, to preserve the controlled‑release properties and ensure consistent drug absorption.

The most serious risks include severe liver injury, pancreatitis, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and blood dyscrasias like thrombocytopenia. Patients should be educated to report symptoms such as jaundice, abdominal pain, rash, or unusual bruising promptly.

Orfiril Long is contraindicated in patients with known hypersensitivity to sodium valproate or any component of the formulation, those with severe hepatic disease, and in pregnant women unless no alternative therapy is available. Caution is also advised for individuals with mitochondrial disorders such as POLG‑related disease.